Pietro Emiliano Doneddu

Pietro Emiliano Doneddu

Auto-generated profile, based on publicly available information

Pietro Emiliano Doneddu

Neuromuscular and Neuroimmunology Unit, IRCCS Humanitas Research Hospital, Italy

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2018 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Open access
PDF file
PDPietro Emiliano Doneddu
Pietro Emiliano Doneddu
DCDario Cocito
Dario Cocito
FMFiore Manganelli
Fiore Manganelli
RFRaffaella Fazio
Raffaella Fazio
CBChiara Briani
Chiara Briani
ENEduardo Nobile-Orazio
Eduardo Nobile-Orazio
Objectives A few variants of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) have been described, but their frequency and evolution to typical CIDP remain unclear. To determine the frequency and characteristics of the CIDP variants, their possible evolution to typical CIDP, and treatment response. Methods We applied a set of diagnostic criteria to 460 patients included in a database of Italian patients with CIDP. Clinical characteristics and treatment response were reviewed for each patient. The Kaplan-Meier curve was used to estimate the progression rate from atypical to typical CIDP. Results At the time of inclusion, 376 (82%) patients had a diagnosis of typical CIDP while 84 (18%) had atypical CIDP, including 34 (7%) with distal acquired demyelinating symmetric neuropathy (DADS), 17 (4%) with purely motor, 17 (4%) with Lewis-Sumner syndrome (LSS) and 16 (3.5%) with purely sensory CIDP. Based on retrospective review of the symptoms and signs present at onset and for at least 1 year, 180 (39%) patients had an initial diagnosis compatible with atypical CIDP that in 96 (53%) patients evolved to typical CIDP. Mean disease duration was longer in patients evolving to typical CIDP than in those not evolving (p=0.0016). Patients with DADS and LSS had a less frequent response to immunoglobulin than those with typical CIDP, while patients with purely motor and sensory CIDP had a similar treatment response. Conclusions The proportion of patients with atypical CIDP varies during the disease course. DADS and LSS have a less frequent response to intravenous immunoglobulin compared with typical CIDP, raising the possibility of a different underlying pathogenetic mechanism.

29 June 2017 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
PDPietro Emiliano Doneddu
Pietro Emiliano Doneddu
Daniele CoraciDaniele Coraci
Daniele Coraci
CLClaudia Loreti
Claudia Loreti
GPGiulia Piccinini
Giulia Piccinini
Luca PaduaLuca Padua
Luca Padua

5 August 2020 in European Journal of Neurology
Verified
Journal Article
Open access
PDF file
PSPaolo De Sanctis
Paolo De Sanctis
PDPietro Emiliano Doneddu
Pietro Emiliano Doneddu
LVLuca Viganò
Luca Viganò
CSCarlo Selmi
Carlo Selmi
ENEduardo Nobile-Orazio
Eduardo Nobile-Orazio
Guillain‐Barré syndrome (GBS) incidence can increase during outbreaks of infectious illnesses. A few cases of GBS associated with coronavirus disease 2019 (COVID‐19) infection have been reported. The aim was to identify specific clinical features of GBS associated with COVID‐19. PubMed, Embase and Cochrane were searched from 1 November 2019 to 17 May 2020 and included all papers with full text in English, Spanish, French or Italian, reporting original data of patients with GBS and COVID‐19. Data were extracted according to a predefined protocol. A total of 18 patients reported in 14 papers were included in this review. All the patients were symptomatic for COVID‐19, with cough and fever as the most frequently reported symptoms. The interval between the onset of symptoms of COVID‐19 and the first symptoms of GBS ranged from −8 to 24 days (mean 9 days; median 10 days). Most of the patients had a typical GBS clinical form predominantly with a demyelinating electrophysiological subtype. Mechanical ventilation was necessary in eight (44%) patients. Two (11%) patients died. Published cases of GBS associated with COVID‐19 report a sensorimotor, predominantly demyelinating GBS with a typical clinical presentation. Clinical features and disease course seem similar to those observed in GBS related to other etiologies. These results should be interpreted with caution since only 18 cases have been heterogeneously reported so far.

2 July 2018 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
GLG. G. A. van Lieverloo
G. G. A. van Lieverloo
SPS. Peric
S. Peric
PDP. E. Doneddu
P. E. Doneddu
FGF. Gallia
F. Gallia
ANA. Nikolic
A. Nikolic
FEF. Eftimov
F. Eftimov
Chronic inflammatory demyelinating polyneuropathy (CIDP) can be treated with corticosteroids or intravenous immunoglobulins. Various corticosteroid regimens are currently used in CIDP, but it is unknown whether they are equally efficacious. In this retrospective study, we compared efficacy and safety of three corticosteroid regimens in CIDP patients.

Verified
Journal Article
Open access
PDF file
FGFrancesco Gentile
Francesco Gentile
PDPietro Emiliano Doneddu
Pietro Emiliano Doneddu
NRNilo Riva
Nilo Riva
ENEduardo Nobile-Orazio
Eduardo Nobile-Orazio
AQAngelo Quattrini
Angelo Quattrini
Increasing evidence gives support for the idea that extra-neuronal factors may affect brain physiology and its predisposition to neurodegenerative diseases. Epidemiological and experimental studies show that nutrition and metabolic disorders such as obesity and type 2 diabetes increase the risk of Alzheimer’s and Parkinson’s diseases after midlife, while the relationship with amyotrophic lateral sclerosis is uncertain, but suggests a protective effect of features of metabolic syndrome. The microbiota has recently emerged as a novel factor engaging strong interactions with neurons and glia, deeply affecting their function and behavior in these diseases. In particular, recent evidence suggested that gut microbes are involved in the seeding of prion-like proteins and their spreading to the central nervous system. Here, we present a comprehensive review of the impact of metabolism, diet and microbiota in neurodegeneration, by affecting simultaneously several aspects of health regarding energy metabolism, immune system and neuronal function. Advancing technologies may allow researchers in the future to improve investigations in these fields, allowing the buildup of population-based preventive interventions and development of targeted therapeutics to halt progressive neurologic disability.

20 July 2019 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
PDP. E. Doneddu
P. E. Doneddu
EBE. Bianchi
E. Bianchi
DCD. Cocito
D. Cocito
FMFiore Manganelli
Fiore Manganelli
RFR. Fazio
R. Fazio
TGthe Italian CIDP Database Study Group
the Italian CIDP Database Study Group